Compare LAZ & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LAZ | WGS |
|---|---|---|
| Founded | 1848 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.6B |
| IPO Year | 2005 | N/A |
| Metric | LAZ | WGS |
|---|---|---|
| Price | $53.26 | $108.65 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $55.00 | ★ $138.13 |
| AVG Volume (30 Days) | ★ 830.2K | 554.5K |
| Earning Date | 01-29-2026 | 02-23-2026 |
| Dividend Yield | ★ 3.75% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.52 | 0.07 |
| Revenue | ★ $3,016,853,000.00 | $402,190,000.00 |
| Revenue This Year | N/A | $41.17 |
| Revenue Next Year | $17.40 | $23.53 |
| P/E Ratio | ★ $21.20 | $1,499.76 |
| Revenue Growth | N/A | ★ 50.50 |
| 52 Week Low | $31.97 | $55.17 |
| 52 Week High | $58.07 | $170.87 |
| Indicator | LAZ | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 60.97 | 26.62 |
| Support Level | $50.15 | $103.01 |
| Resistance Level | $53.16 | $113.24 |
| Average True Range (ATR) | 1.63 | 8.17 |
| MACD | 0.34 | -2.74 |
| Stochastic Oscillator | 80.10 | 13.21 |
Lazard Inc has a storied history that can be traced back to 1848. The company's revenue is fairly evenly split between financial advisory, such as acquisition and restructuring advisory, and asset management. The company's asset management business is primarily driven by equities (over 80% of assets under management), has an international focus, and targets institutional clients. By geography, the company earns approximately 60% of revenue in the Americas, 35% in EMEA, and 5% in Asia-Pacific. Lazard has offices across more than 20 countries and over 3,000 employees.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.